Brought to you by 
Xoma to help develop Genentech's anti-CD11a monoclonal
14 May 2003
Executive Summary
Genentech has engaged monoclonal antibody specialist Xoma Corp. to assist in the development of its anti-CD11a antibody, a potential treatment for psoriasis and organ transplant rejection, in exchange for a potential $20mm in equity and loans, up-front money, milestones, and royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xoma to help develop Genentech's anti-CD11a monoclonal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice